

## MANUFACTURER STATEMENT

## MANUFACTURER STATEMENT EU MDR 2017/745 DECLARATION

## PHTHALATES, SUBSTANCES CARCINOGENIC, MUTAGENIC OR TOXIC TO REPRODUCTION

The ADMEDES Group (hereinafter referred to as ADMEDES) hereby confirms that the components / parts of medical devices produced for our customers do not incorporate as integral parts phthalates and substances which are carcinogenic, mutagenic, or toxic to reproduction at levels above 0,1%w/w. This is in accordance to the hazardous substance lists referenced in the EU MDR – REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 5 APRIL 2017 Section 10.4.1:

- EU Classification, Labelling and Packaging (EC) No 1272/2008 for substances which are carcinogenic, mutagenic or toxic to reproduction (CMR), of category 1A or 1B, Annex VI to CLP ATP17 in force 17 Dec 2022 and CLP ATP 18 ( Shall apply 23 Nov 2023 )
- EU REACH (EC) No 1907/2006 for substances having endocrine-disrupting properties, published in accordance with Article 59 (10) of the REACH Regulation updated **17 Jan 2023**.
- The Biocidal Products Regulation (BPR), Regulation (EU) 528/2012 for substances having endocrine-disrupting (ED) properties for human health, in print as of 23 Jan 2023.

1 A. But

For and on behalf of ADMEDES

Signed in Pforzheim

Date: 28/04/2023

i.V. Andreas Butz

Bereichsleiter Prozessbetreuung

Vice President Process Engineering

**ADMEDES GmbH** 

Rastatter Str. 15 | 75179 Pforzheim, Germany

Tel.: +49 7231 92231-261 Fax: +49 7231 92231-99

Cell: +49 162 2621761

E-Mail: <u>abutz@admedes.com</u> | <u>admedes.com</u>

This information is believed to be accurate and refers to the laws, regulations and products at the date of issue. However, ADMEDES makes no express or implied representations or warranties with respect to the information contained herein. It is the responsibility of our customers to determine that their products are safe, lawful, and technically suitable for their applications. Because of possible changes in the laws and regulations, we cannot guarantee that the status of this article will remain unchanged.